Clinical study on trimetazidine in treatment of coronary heart disease complicated with cardiac insufficiency

Objective To explore the efficacy of trimetazidine in treatment of coronary heart disease complicated with cardiac insufficiency. Methods Patients(92 cases) with coronary heart disease complicated with cardiac insufficiency from February 2011 to January 2014 were randomly divided into treatment(46 cases) and control(46 cases) groups. The patients in the control group were given conventional treatment. The patients in the treatment group were po administered with Trimetazidine Tablets, 20 mg/time, three times daily. The patients in the two groups were treated for 4 months. After the treatment, the treatment efficacy was evaluated, while the changes of myocardial enzyme spectrum and indexes of cardiac function were compared. Results The significant efficiency in the treatment and control groups were 58.70% and 34.78%, respectively, and there were differences between the two groups(P 0.05). After treatment, c Tn I, c Tn T, CK-MB, and Mb were decreased significantly in two groups on day 3 of treatment, and the difference was statistically significant in the same group(P 0.05). After treatment, these indexes in treatment group were lower than those in the control group, with the significant difference between two groups(P 0.05). After treatment, LVEDD, LVESD, and MAP in two groups were decreased significantly, and LVEF was elevated, and the differences were statistically significant in the same group(P 0.05). After treatment, these indicators in the treatment group improved better than those of control group, with the significant difference between two groups(P 0.05). Conclusion Trimetazidine has good clinical effect in treatment of coronary heart disease complicated with cardiac insufficiency, and can improve situation of myocardial damage and promote recovery of heart function, which is worthy of clinical application.